Relation of Haptoglobin Phenotype to Early Vascular Changes in Patients With Diabetes Mellitus

American Journal of Cardiology

Volumn 100, Issue 12, 2007, Pages 1767-1770

  Shor, Marina ^a   Boaz, Mona ^a   Gavish, Dov ^a   Wainshtein, Julio ^a   Matas, Zipora ^a   Shargorodsky, Marina ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HAPTOGLOBIN;

ADULT; AGED; ARTERY COMPLIANCE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ELASTICITY; FEMALE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PULSE WAVE; VASCULAR RESISTANCE;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ELASTICITY; FEMALE; HAPTOGLOBINS; HEMODYNAMICS; HEMORHEOLOGY; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; TIME FACTORS; VASCULAR RESISTANCE;

EID: 36849095720     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.052     Document Type: Article

References (23)

1. Cohn J.N., Finkelstein S., McVeigh G., Morgan D., LeMay I., Robinson J., and Mock J. Non-invasive pulse wave analysis for the detection of arterial vascular disease. Hypertension 26 (1995) 503-508
2. Salomaa V., Riley W., Kark J.D., Nardo C., and Folsom A.R. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentration are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 91 (1995) 1432-1443
3. van Popele N.M., Grobbee D.E., Bots M.L., Asmar R., Topouchian J., Reneman R.S., Hoeks A.P., van der Kuip D.A., Hofman A., and Witteman J.C. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 32 (2001) 454-460
4. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., and London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999) 2434-2439
5. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., Ducimetiere P., and Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (2001) 1236-1241
6. Cruickshank K., Riste L., Anderson S.G., Wright J.S., Dunn G., and Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance. An integrated index of vascular function?. Circulation 106 (2002) 2085-2090
7. Zieman S.J., Melenovsky V., and Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005) 932-943
8. Giannattasio C., and Mancia G. Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment. J Hypertens 20 (2002) 1889-1899
9. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 285 (2001) 2486-2497
10. Langllois M.R., and Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42 (1996) 1589-1600
11. Smithies O. Zone electrophoresis in starch gels: group variations in the serum proteins of normal human adults. Biochemistry 61 (1955) 629-641
12. Shargorodsky M., Leibovitz E., Lubimov L., Gavish D., and Zimlichman R. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential arterial hypertension. Am J Hypertens 15 (2002) 1087-1091
13. McVeigh G.E., Burns D.E., Finkelstein S.M., McDonald K.M., Mock J.E., Feske W., Carlyle P.F., Flack J., Grimm R., and Conh J.N. Reduced vascular compliance as a marker for essential hypertension. Am J Hypertens 4 (1991) 245-257
14. Zimlichman R., Shargorodsky M., Boaz M., Duprez D., Rahn K.H., Rizzoni D., Payeras A.C., Hamm C., and McVeigh G. Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 system. Am J Hypertens 18 (2005) 65-71
15. Levy A.P., Roguin A., Marsh S., Nakhoul F.M., Herer P., Hochberg I., and Skorecki K. Haptoglobin phenotype and vascular complications in diabetes. N Engl J Med 343 (2000) 969-970
16. Nakhoul F., Marsh S., Hochberg I., Leibu R., Miller B.P., and Levy A.P. Haptoglobin phenotype and diabetic retinopathy. JAMA 284 (2000) 1244-1245
17. Levy A.P., Hochberg I., Jablonski K., Resnic H.E., Lee E.T., Best L., and Howard B.V. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol 40 (2002) 1984-1990
18. Suleiman M., Aronson D., Asleh R., Kapeliovich M.R., Roguin A., Meisel S.R., Shochat M., Sulieman A., Reisner S.A., Markiewicz W., et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 54 (2005) 2802-2806
19. Guigliano D., Ceriello A., and Paolisso G. Oxidative stress and diabetic vascular complications. Diabetic Care 19 (1996) 257-267
20. Gutteridge J.M. The antioxidant activity of haptoglobin towards hemoglobin-stimulated lipid peroxidation. Biochem Biophys Acta 917 (1987) 219-223
21. Collins P., Burman J., Chung H., and Fox K. Hemoglobin inhibits endothelium-dependent relaxation to acetylcholine in human coronary arteries in vivo. Circulation 87 (1993) 80-85
22. Delanghe J., Duprez D., De Buyzere M., Bergez B., Callens B., Leroux-Roels G., and Clement D. Haptoglobin phenotypes and complications in established essential arterial hypertension. J Hypertens 11 (1993) 861-867
23. Braeckman L., De Bacquer D., Delanghe J., Claeys L., and De Backer G. Association between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis 143 (1999) 383-388